Teva CEO sold 250,000 shares under a plan
Teva Pharmaceutical Industries Ltd. chief executive officer Richard D. Francis sold 250,000 company shares on November 10, 2026. The deal was executed under a Rule 10b5-1 trading plan, a preset selling schedule executives set up in advance.
Key points
- Beyond the chief executive officer, other executives also reported stock transactions.
- The company also reported directors and officers received new conditional shares (derivative securities).
Insider activity and ownership changes
Beyond the chief executive officer, other executives also reported stock transactions. Richard Daniell, executive vice president of Europe commercial, exercised 45,003 options and sold an equal number of shares between November 9 and 11. Mark Sabag, executive vice president of international markets commercial, exercised 44,710 options and sold 44,710 shares on November 12.
Phoenix Financial Ltd. released a report stating it held 56,550,148.77 Teva shares as of November 4, 2026, representing a 4.85% stake in the company.
Value of shares sold, by insider
Other events and appointments
The company also reported directors and officers received new conditional shares (derivative securities). Specifically, director David J. Brailer received 3,326 units, and interim chief legal officer Dov Bergwerk received 9,433 units on November 10, 2026.
What to watch
Shareholders should monitor further ownership change reports from Phoenix Financial Ltd. via the SEC EDGAR system. Such changes in reporting by major institutional investors may signal shifting sentiment among large capital holders regarding the company.
Original sources
- 3 filing, November 12, 2026
- 4 filing, November 12, 2026
- 4 filing, November 12, 2026
- 4 filing, November 12, 2026
- 4 filing, November 12, 2026
- 4 filing, November 12, 2026
- SCHEDULE 13G/A filing, November 16, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Teva Pharmaceutical Industries
A notification in your browser or on your phone when we publish about Teva Pharmaceutical Industries. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
